Efficacy and Safety of Bleselumab in Preventing the Recurrence of Primary Focal Segmental Glomerulosclerosis in Kidney Transplant Recipients: A Phase 2a, Randomized, Multicenter Study
dc.contributor.author | Shoji, Jun | |
dc.contributor.author | Goggins, William C. | |
dc.contributor.author | Wellen, Jason R. | |
dc.contributor.author | Cunningham, Patrick N. | |
dc.contributor.author | Johnston, Olwyn | |
dc.contributor.author | Chang, Shirley S. | |
dc.contributor.author | Solez, Kim | |
dc.contributor.author | Santos, Vicki | |
dc.contributor.author | Larson, Tami J. | |
dc.contributor.author | Takeuchi, Masahiro | |
dc.contributor.author | Wang, Xuegong | |
dc.contributor.department | Surgery, School of Medicine | |
dc.date.accessioned | 2024-09-20T10:38:24Z | |
dc.date.available | 2024-09-20T10:38:24Z | |
dc.date.issued | 2024 | |
dc.description.abstract | Background: Focal segmental glomerulosclerosis (FSGS) is a common cause of end-stage kidney disease and frequently recurs after kidney transplantation. Recurrent FSGS (rFSGS) is associated with poor allograft and patient outcomes. Bleselumab, a fully human immunoglobulin G4 anti-CD40 antagonistic monoclonal antibody, disrupts CD40-related processes in FSGS, potentially preventing rFSGS. Methods: A phase 2a, randomized, multicenter, open-label study of adult recipients (aged ≥18 y) of a living or deceased donor kidney transplant with a history of biopsy-proven primary FSGS. The study assessed the efficacy of bleselumab combined with tacrolimus and corticosteroids as maintenance immunosuppression in the prevention of rFSGS >12 mo posttransplantation, versus standard of care (SOC) comprising tacrolimus, mycophenolate mofetil, and corticosteroids. All patients received basiliximab induction. The primary endpoint was rFSGS, defined as proteinuria (protein-creatinine ratio ≥3.0 g/g) with death, graft loss, or loss to follow-up imputed as rFSGS, through 3 mo posttransplant. Results: Sixty-three patients were followed for 12 mo posttransplantation. Relative decrease in rFSGS occurrence through 3 mo with bleselumab versus SOC was 40.7% (95% confidence interval, -89.8 to 26.8; P = 0.37; absolute decrease 12.7% [95% confidence interval, -34.5 to 9.0]). Central-blinded biopsy review found relative (absolute) decreases in rFSGS of 10.9% (3.9%), 17.0% (6.2%), and 20.5% (7.5%) at 3, 6, and 12 mo posttransplant, respectively; these differences were not statistically significant. Adverse events were similar for both treatments. No deaths occurred during the study. Conclusions: In at-risk kidney transplant recipients, bleselumab numerically reduced proteinuria occurrence versus SOC, but no notable difference in occurrence of biopsy-proven rFSGS was observed. | |
dc.eprint.version | Final published version | |
dc.identifier.citation | Shoji J, Goggins WC, Wellen JR, et al. Efficacy and Safety of Bleselumab in Preventing the Recurrence of Primary Focal Segmental Glomerulosclerosis in Kidney Transplant Recipients: A Phase 2a, Randomized, Multicenter Study. Transplantation. 2024;108(8):1782-1792. doi:10.1097/TP.0000000000004985 | |
dc.identifier.uri | https://hdl.handle.net/1805/43457 | |
dc.language.iso | en_US | |
dc.publisher | Wolters Kluwer | |
dc.relation.isversionof | 10.1097/TP.0000000000004985 | |
dc.relation.journal | Transplantation | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | en |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.source | PMC | |
dc.subject | Adrenal cortex hormones | |
dc.subject | Immunosuppressive agents | |
dc.subject | Tacrolimus | |
dc.subject | Chronic kidney disease | |
dc.title | Efficacy and Safety of Bleselumab in Preventing the Recurrence of Primary Focal Segmental Glomerulosclerosis in Kidney Transplant Recipients: A Phase 2a, Randomized, Multicenter Study | |
dc.type | Article |